Difference between revisions of "Team:Oxford/test2"

Line 308: Line 308:
  
 
<!-- Start of content -->
 
<!-- Start of content -->
−
<div id="contentContainer"></div><!--The closing tag for contentContainer should be placed at the bottom of each content page.-->
+
<div id="contentContainer"><img class="displayed" src="https://static.igem.org/mediawiki/2015/7/79/Team_oxford_cartoon1.jpg" alt="cartoon1" style="width:800px;height:390px;float:center">
 +
<br>
 +
 
 +
<h1>Project Overview</h1>
 +
<br>
 +
<br>
 +
<p class="text">We are interested in developing an autonomous antibacterial system using an E. coli chassis through synthetic biology. Our antibacterial strategy involves a two-step mechanism: <ul>
 +
<p>i) Destroy the bacterial biofilm which confers the bacteria encased within significantly increased resilience against antibiotics. </p>
 +
<p>ii) Destroy the liberated bacteria by directly lysing their cell walls.</p>
 +
</ul>
 +
</p>
 +
 
 +
<p>We will be experimenting with antibacterial action against E. coli and P. aeruginosa. </p>
 +
<br>
 +
 
 +
<p>Our project was initially inspired by our teammate George's work at a urinary tract infection (UTI) clinic last summer. Click <a href="https://2015.igem.org/Team:Oxford/Backdrop">here</a> to find out more about our backstory!</p>
 +
<br>
 +
 
 +
<h3>Antibiofilm action</h3>
 +
 
 +
<p class="text">The cartoon above shows two of the major structural components of bacterial biofilms - extracellular polymeric substance (a.k.a. EPS, in <span class="blue">blue</span>) and extracellular DNA (in <span class="pink">pink</span>). The UTILYSE system will release the following enzymes targeting these structural components:
 +
<ul>
 +
<table>
 +
  <tr>
 +
    <td>Dispersin B</td>
 +
    <td>Destroys E. coli biofilms by hydrolysing beta-1,6-N-acetyl-D-glucosamine, which is the major EPS in E. coli biofilms</td>
 +
  </tr>
 +
  <tr>
 +
    <td>Thermonuclease</td>
 +
    <td>Also commonly known as staphylococcal nuclease, this enzyme should be able to destroy P. aeruginosa biofilms by hydrolysing its extracellular DNA (novel usage, untested as of yet)</td>
 +
</tr>
 +
</table>
 +
</ul>
 +
</p>
 +
<br>
 +
<h3>Antibacterial action</h3>
 +
 
 +
<p class="text">UTILYSE will release "artilysins", which is a class of combination biomolecules made by fusing endolysins (phage-derived enzymes that hydrolyse bacterial cell walls) with SMAP-29 (a transporter peptide that brings the complex through the bacterial outer membrane such that it can get in contact with the cell wall). Endolysins are species-selective in terms of the type of cell wall which they hydrolyse, and as such UTILYSE will be making two different artilysins:
 +
<ul>
 +
<table>
 +
  <tr>
 +
    <td>Art-175</td>
 +
    <td>An artilysin specific for P. aeruginosa comprising endolysin KZ-144 and SMAP-29, invented in 2013</td>
 +
  </tr>
 +
  <tr>
 +
    <td>Art-E</td>
 +
    <td>An E. coli-specific artilysin, comprising T4 endolysin and SMAP-29, conceptualized and designed by our team (novel design, untested as of yet)</td>
 +
</tr>
 +
</table>
 +
</ul>
 +
</p>
 +
<br>
 +
 
 +
<h3>Overall design</h3>
 +
<p class="text">We intend to construct two variations of UTILYSE - one that synthesizes and accumulates the antibacterials and antibiofilms within itself before releasing them all by self-lysing upon detection of the presence of group pathogenic bacteria behaviour (via quorum sensing), and another one that constantly secretes moderate levels of both antibacterials and antibiofilms. With the secretor design, we are also interested in studying the secretion efficiency of our biomolecules of interest through different secretion mechanisms.<br><br>
 +
Read more about how UTILYSE can perform quorum sensing-triggered release of bacterilytics/antibiofilms <a href="https://2015.igem.org/Team:Oxford/Description/QS">here</a>.</p>
 +
<br>
 +
 
 +
<h3>Potential applications</h3>
 +
<p class="text">Given that our original inspiration leading up to us looking at biofilms contributing to the overarching problem of antibiotic resistance was urinary tract infections, we are definitely interested in exploring how we can incorporate this biotechnology as a form of prophylactic application for preventing recurrent, nasty biofilm-mediated infections from forming on indwelling urinary catheters. Other than that, UTILYSE can also potentially be used in antibiofilm plasters or even industrial contexts such as self-cleaning, antifouling pipelines.</p>
 +
 
 +
</div></div><!--The closing tag for contentContainer should be placed at the bottom of each content page.-->
  
  
 
</html>
 
</html>

Revision as of 21:31, 9 July 2015

Team Oxford
cartoon1

Project Overview



We are interested in developing an autonomous antibacterial system using an E. coli chassis through synthetic biology. Our antibacterial strategy involves a two-step mechanism:

    i) Destroy the bacterial biofilm which confers the bacteria encased within significantly increased resilience against antibiotics.

    ii) Destroy the liberated bacteria by directly lysing their cell walls.

We will be experimenting with antibacterial action against E. coli and P. aeruginosa.


Our project was initially inspired by our teammate George's work at a urinary tract infection (UTI) clinic last summer. Click here to find out more about our backstory!


Antibiofilm action

The cartoon above shows two of the major structural components of bacterial biofilms - extracellular polymeric substance (a.k.a. EPS, in blue) and extracellular DNA (in pink). The UTILYSE system will release the following enzymes targeting these structural components:

    Dispersin B Destroys E. coli biofilms by hydrolysing beta-1,6-N-acetyl-D-glucosamine, which is the major EPS in E. coli biofilms
    Thermonuclease Also commonly known as staphylococcal nuclease, this enzyme should be able to destroy P. aeruginosa biofilms by hydrolysing its extracellular DNA (novel usage, untested as of yet)


Antibacterial action

UTILYSE will release "artilysins", which is a class of combination biomolecules made by fusing endolysins (phage-derived enzymes that hydrolyse bacterial cell walls) with SMAP-29 (a transporter peptide that brings the complex through the bacterial outer membrane such that it can get in contact with the cell wall). Endolysins are species-selective in terms of the type of cell wall which they hydrolyse, and as such UTILYSE will be making two different artilysins:

    Art-175 An artilysin specific for P. aeruginosa comprising endolysin KZ-144 and SMAP-29, invented in 2013
    Art-E An E. coli-specific artilysin, comprising T4 endolysin and SMAP-29, conceptualized and designed by our team (novel design, untested as of yet)


Overall design

We intend to construct two variations of UTILYSE - one that synthesizes and accumulates the antibacterials and antibiofilms within itself before releasing them all by self-lysing upon detection of the presence of group pathogenic bacteria behaviour (via quorum sensing), and another one that constantly secretes moderate levels of both antibacterials and antibiofilms. With the secretor design, we are also interested in studying the secretion efficiency of our biomolecules of interest through different secretion mechanisms.

Read more about how UTILYSE can perform quorum sensing-triggered release of bacterilytics/antibiofilms here.


Potential applications

Given that our original inspiration leading up to us looking at biofilms contributing to the overarching problem of antibiotic resistance was urinary tract infections, we are definitely interested in exploring how we can incorporate this biotechnology as a form of prophylactic application for preventing recurrent, nasty biofilm-mediated infections from forming on indwelling urinary catheters. Other than that, UTILYSE can also potentially be used in antibiofilm plasters or even industrial contexts such as self-cleaning, antifouling pipelines.